Navigation Links
Mylan Reiterates and Stands Behind Its 48-Year Commitment and Track Record of Quality
Date:7/26/2009

PITTSBURGH, July 26 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) released the following response to a news article published earlier today:

"An article published today about an issue related to a Standard Operating Procedure (SOP) was based on improperly obtained documents, uninformed third-party commentary and anonymous sources. Simply put, our investigation of the issue demonstrates that our quality systems are working, not the contrary. Our customers and stakeholders can rest assured that whenever there is even the slightest departure from an SOP, it will be dealt with immediately and effectively. This issue had no impact on the quality of our product."

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
2. Mylan Declares Quarterly Preferred Stock Dividend
3. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
4. Mylan Schedules Second Quarter 2009 Financial Results Conference Call and Live Webcast
5. Mylan Receives FDA Approval for Additional Strength of Generic Restoril(R)
6. Mylans Chief Operating Officer Heather Bresch to Testify Before Congress Concerning Patent Settlements Between Brand and Generic Pharmaceutical Companies and Tactics That Delay Market Entry of High Quality, Affordable Generic Drugs
7. Mylan Announces Successful Matrix Delisting Offer
8. Mylan Announces Change in Board Leadership
9. Mylan Receives Final FDA Approvals for Generic Versions of Anti-Rejection Medication CellCept(R)
10. Mylan Schedules First Quarter 2009 Financial Results Conference Call and Live Webcast
11. Mylan Declares Quarterly Preferred Stock Dividend

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2009)...5 years, the number of Americans living with diabe...on in 2009 to 44.1 million in 2034. Over the same ...ising from $113 billion to $336 billion, even with...hers based at the University of Chicago report in ...ber of those with diabetes covered by Medicare wil...
(Date:11/26/2009)... Dr. David Kim of the Live Life Again Ce...Dallas , is one of a growing number of physicians ...king sites to connect with individuals who are int... morbid obesity. Dr. Kim is utilizing Facebook to ...t his practice with the community. , ...
(Date:11/25/2009)...ITY,Mo.,Nov.25/PRNewswire/--TheBartleHallConventio...calcliniconDec.9-10,whenKansasCityhoststhelatestin..., "Thisfreecliniceventhasthepotentialtobethebigge...stoneandbeheldonweekdaysinsteadofoveraweekend,"She...linicandpresidentoftheNationalAssociationofFreeCli...
(Date:11/25/2009)...PRING,Md.,Nov.25/PRNewswire-USNewswire/--Anarticle...ugEvaluationandResearch,titled"ADifficultBalance-P...v.26,2009issueofTheNewEnglandJournalofMedicine. ,...90824/FDALOGO ) ,, Inthearticle,Woodcockdiscuss...icationforthosewhoneeditandmanagingtherisksposedby...
(Date:11/25/2009)...ave found evidence of a statistically significant ...ients whose estrogen receptor (ER)-positive tumors...t serine-118 (ER-alpha S118-P), according to a bri...he Journal of the National Cancer Institute . , ...ant to tamoxifen. Preclinical studies have shown t...
Breaking Medicine News(10 mins):Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Kansas City Prepares for Largest Free Health Clinic 2
...ident of India - Dr. Avul Pakir Jainulabdeen Abdul...Padma Bhushan and Padma Shri - on the eve of the R... ‘Awards Committee’ makes the final recommendation... of excellence, and the names have to be finally c...
...w report finds that less number of women aged 40 a... This declining mammography rate could mean m...to concerned experts. Mammography rates kep... a test that's been around for a long time, it's s...
...cent study finds that a simple blood test may be a.../ head and neck cancer as a result of smoking. ... of the Weizmann Institute's Biological Chemistry ...r, Prof. Laurence Freedman of Sheba Medical Center...
...land has okayed the issue of compulsory licenses f...drugs,// a move, not likely to sit well with pharm...la, confirmed that the laws are in place and are e...gs would be generic substitutes to products from A...
...technology, which has been developed by the Bath I...ol for Health //at the University of Bath, has bee...o living on their own after a stay in hospital. ...t can wirelessly ‘talk’ to devices, such as the co...
...York – When women think of cancer, it is breast ca...It might be an eye opener to know that more women ...w report that emerged after a discussion amongst r... increase in women smokers. In 2000, lung cancer d...
Other Medicine News:Health News:Majority of Padma Awards Go to Doctors from Delhi 2Health News:Mammography Saves Life-Beware Women Over 40 2Health News:Scientists Identity Genetic Risk Factor for Head and Neck Cancer 2Health News:‘Smart Way of Living’ for Dementia Patien 2
(Date:11/25/2009)...inker.comannouncesthatanewmarketresearchreportisav...vicesMarketAnalysisandForecaststo2015 ,, http...tal-Devices-Market-Analysis-and-Forecasts-to-2015....sandForecaststo2015 ,, Summary ,, Thisrepo...relatingtotheUSdentaldevicesmarket.Italsooffersdet...
(Date:11/25/2009)...l/--NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevicecom...ivesurgicaltreatmentsforthespine,announcedtodaytha...,at5:30p.m.ET/2:30p.m.PT.Theconferencecallwillfocu...ny,sproductsandwillincludecommentsfrommanagementfo...umbersare1-877-407-4018fordomesticcallersand1-201-...
(Date:11/25/2009)...Newswire-FirstCall/--HeartWareInternational,Inc.(N...oflessinvasive,miniaturizedcirculatorysupporttechn...ailure,todayannouncedthatitisscheduledtomakeaninve...areConferenceat8:00amESTonWednesday,December2,2009...ecember1-2. ,, AlivewebcastoftheCompany,spresen...
Breaking Medicine Technology:Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 2Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 3Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 4Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 5Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 6Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 7Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 8Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 9Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 10Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 11Reportlinker Adds United States Dental Devices Market Analysis and Forecasts to 2015 12NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3ClariVein 28TM 29 Catheter for Varicose Veins 3A Clinical Trial Results to be Presented 4922 1ClariVein 28TM 29 Catheter for Varicose Veins 3A Clinical Trial Results to be Presented 4922 2Tests Confirm HandClens 28R 29 Hand Sanitizer Kills H1N1 Flu Virus 55725 1Tests Confirm HandClens 28R 29 Hand Sanitizer Kills H1N1 Flu Virus 55725 2Tests Confirm HandClens 28R 29 Hand Sanitizer Kills H1N1 Flu Virus 55725 3Transcend Medical Expands Leadership Team Appointing Chief Medical Officer and Vice President of Clinical Affairs 55722 1Transcend Medical Expands Leadership Team Appointing Chief Medical Officer and Vice President of Clinical Affairs 55722 2
...inical and Phase 1 Data Scheduled for Presentation... 18-19, 2007 -, CARLSBAD, Calif., Sept. 4 Ardea ...ay that it has successfully completed,Phase 1 sing...ffect, and,drug-interaction studies of RDEA806, a ...ibitor (NNRTI), in healthy volunteers. The data f...
...AKES, Fla., Sept. 4 In an extensive analysis of,c...R(R) Sirolimus-eluting,Coronary Stent was associat...nd the need for reintervention compared to the Tax...cedure. This meta-analysis of 16 randomized,clinic... of its kind to,date, is now posted on the Journal...
Other Medicine Technology:Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806 2Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806 3Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 2Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 3Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent 4
...tretch Vascular Grafts have met the challenges of ... for exceptional performance and quality, they hav...dwide. These grafts require no preclotting, resist...e utmost thrombectomy safety. The GORE-TEX Stretch...
...olving techniques for vascular surgery, and the ac...that new, specialized types of graft be developed....atible, but also available in varying sizes and co...X Vascular Graft has long been the prosthetic of c...
...ascular Grafts have met the challenges of the most...Recognized for exceptional performance and quality...geons worldwide. These grafts require no preclotti... and assure utmost thrombectomy safety. The Gore v...
...eg; Vascular Grafts have met the challenges of the...ars. Recognized for exceptional performance and qu...d surgeons worldwide. These grafts require no prec...tion, and assure utmost thrombectomy safety. Gore ...
Medicine Products: